ARCHIVED: Appendix 7a: The Management of the National Antiviral Stockpile: Options Report - Purchase requirements, by jurisdiction, to meet paediatric oseltamivir, zanamivir, and amantadine targets
Notes: 1 2008 Population Estimates: Total population >1 year of age = 33 million; total paediatric population (1-<12) = 4 million; total adult population (12+) = 29 million 2 P/T Proportions Used: 2008 total population census data 3 There are already approx. 2 million paediatric oseltamivir capsules already in the NAS and distributed to P/Ts on a per capita basis, the table reflects the remaining 7.2 million doses to be purchased. 4 NT adult oseltamivir stock does not expire until 2011. Options to be discussed with PWGSC in order to meet paediatric targets through Exchange program, etc. |
|||||
Jurisdiction2 | Remaining doses3 paediatric oseltamivir to be purchased | Zanamivir paediatric doses | Zanamivir adult doses | Amantadine doses (additional 10% of NAS) | |
---|---|---|---|---|---|
30 mg capsules | 45 mg capsules | ||||
NAS |
5,923,165 |
1,247,983 |
700,000 |
5,000,000 |
5,800,000 |
NL (1.5%) |
87,439 |
20,414 |
10,673 |
76,234 |
88,432 |
PEI (.4%) |
24,233 |
5,650 |
2,938 |
20,987 |
24,344 |
NS (2.8%) |
162,247 |
37,979 |
19,717 |
140,839 |
163,373 |
NB (2.2%) |
130,062 |
30,555 |
15,704 |
112,169 |
130,116 |
QC (23.3%) |
1,348,612 |
316,832 |
162,868 |
1,163,341 |
1,349,476 |
ON (38.8%) |
2,374,679 |
414,366 |
271,688 |
1,940,627 |
2,251,127 |
MB (3.6%) |
210,417 |
49,418 |
25,384 |
181,313 |
210,323 |
SK (3%) |
160,920 |
36,240 |
21,350 |
152,498 |
176,898 |
AB (10.8%) |
637,638 |
151,279 |
75,338 |
538,126 |
624,226 |
BC (13.2%) |
768,006 |
180,894 |
92,074 |
657,673 |
762,901 |
YK (.1%) |
5,885 |
1,361 |
696 |
4,975 |
5,771 |
NT (.1%) |
7,5144 |
1,7304 |
910 |
6,497 |
7,536 |
NU (.1%) |
5,512 |
1,266 |
661 |
4,720 |
5,476 |
Page details
- Date modified: